Tifluadom HCl

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 125402

CAS#: 96337-50-7 (HCl)

Description: Tifluadom is a kappa-opioid benzodiazepine.

Chemical Structure

img
Tifluadom HCl
CAS# 96337-50-7 (HCl)
Instruction

Theoretical Analysis

MedKoo Cat#: 125402
Name: Tifluadom HCl
CAS#: 96337-50-7 (HCl)
Chemical Formula: C22H21ClFN3OS
Exact Mass: 429.11
Molecular Weight: 429.940
Elemental Analysis: C, 61.46; H, 4.92; Cl, 8.25; F, 4.42; N, 9.77; O, 3.72; S, 7.46

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 96337-50-7 (HCl)   83386-35-0 (free base)  

Synonym: Tifluadom Hydrochloride; 96337-50-7; RQB9JWT8M3; DTXSID80858485

IUPAC/Chemical Name: N-((5-(2-fluorophenyl)-1-methyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-2-yl)methyl)thiophene-3-carboxamide hydrochloride

InChi Key: JFZSUQQSHDYRGA-UHFFFAOYSA-N

InChi Code: InChI=1S/C22H20FN3OS.ClH/c1-26-16(13-25-22(27)15-10-11-28-14-15)12-24-21(17-6-2-4-8-19(17)23)18-7-3-5-9-20(18)26;/h2-11,14,16H,12-13H2,1H3,(H,25,27);1H

SMILES Code: Cl.CN1C(CNC(=O)C2=CSC=C2)CN=C(C3=CC=CC=C3F)C4=CC=CC=C14

Appearance: To be determined

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 429.94 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Genovese RF, Dykstra LA. Tifluadom's effects under electric shock titration and tail-immersion procedures in squirrel monkeys. Life Sci. 1986 Nov 10;39(19):1713-9. PubMed PMID: 3773641.

2: Gericke M, Morgenstern R, Ott T. The influence of tifluadom on cholecystokinin-induced antinociception. Eur J Pharmacol. 1990 May 3;180(1):187-90. PubMed PMID: 2365002.

3: Cooper SJ, Moores WR, Jackson A, Barber DJ. Effects of tifluadom on food consumption compared with chlordiazepoxide and kappa agonists in the rat. Neuropharmacology. 1985 Sep;24(9):877-83. PubMed PMID: 2997653.

4: Das S, Bhargava HN. Inhibition of [3H][3-MeHis2]thyrotropin releasing hormone recognition sites in the rat brain by tifluadom, a kappa opiate receptor agonist. Neuropharmacology. 1987 Aug;26(8):1141-6. PubMed PMID: 2889163.

5: Shearman GT, Tolcsvai L. Tifluadom-induced diuresis in rats. Evidence for an opioid receptor-mediated central action. Neuropharmacology. 1986 Aug;25(8):853-6. PubMed PMID: 3022178.

6: Chang RS, Lotti VJ, Chen TB, Keegan ME. Tifluadom, a kappa-opiate agonist, acts as a peripheral cholecystokinin receptor antagonist. Neurosci Lett. 1986 Dec 12;72(2):211-4. PubMed PMID: 3027627.

7: Benton D, Smoothy R, Brain PF. Comparisons of the influence of morphine sulphate, morphine-3-glucuronide and tifluadom on social encounters in mice. Physiol Behav. 1985 Nov;35(5):689-93. PubMed PMID: 3001798.

8: Pavone F, Castellano C. Effects of tifluadom on passive avoidance behaviour in DBA/2 mice. Behav Brain Res. 1985 May;15(3):177-81. PubMed PMID: 2988580.

9: Morley JE, Levine AS, Grace M, Kneip J, Zeugner H. The effect of the opioid-benzodiazepine, tifluadom, on ingestive behaviors. Eur J Pharmacol. 1983 Sep 30;93(3-4):265-9. PubMed PMID: 6315453.

10: Murray C, Cowan A. Neuroadaptation of rats to kappa agonists U-50,488 and tifluadom. NIDA Res Monogr. 1988;81:136-42. PubMed PMID: 2841602.

11: Ureta H, López LF, Pérez A, Huidobro-Toro JP. Kappa-opiate-induced diuresis and changes in blood pressure: demonstration of receptor stereoselectivity using (+)- and (-)-tifluadom. Eur J Pharmacol. 1987 Mar 31;135(3):289-95. PubMed PMID: 3034631.

12: Petrillo P, Amato M, Tavani A. The interaction of the two isomers of the opioid benzodiazepine tifluadom with mu-, delta-, and kappa-binding sites and their analgesic and intestinal effects in rats. Neuropeptides. 1985 Feb;5(4-6):403-6. PubMed PMID: 2860598.

13: Jackson HC, Sewell RD. The role of opioid receptor sub-types in tifluadom-induced feeding. J Pharm Pharmacol. 1984 Oct;36(10):683-6. PubMed PMID: 6150086.

14: Upton N, Gonzalez JP, Sewell RD. Characterization of a kappa-agonist-like antinociceptive action of tifluadom. Neuropharmacology. 1983 Oct;22(10):1241-2. PubMed PMID: 6316195.

15: Järvinen A. Atipamezole, benzodiazepines, bicucullin and tifluadom antagonize the effect of TRH on rat duodenum and displace it from brain and anterior pituitary receptors. Pharmacol Toxicol. 1991 May;68(5):371-9. PubMed PMID: 1658766.

16: Burkard WP, Müller PM, Flück N. Characteristics of 3H-tifluadom binding in guinea-pig brain membranes. J Recept Res. 1984;4(1-6):165-73. PubMed PMID: 6151988.

17: Leander JD. Kappa-opioid diuretic effects of tifluadom, a benzodiazepine opioid agonist. J Pharm Pharmacol. 1984 Aug;36(8):555-6. PubMed PMID: 6148404.

18: Sansone M, Castellano C, Pavone F, Hano J. Opioid benzodiazepine tifluadom and drug-induced hyperactivity in mice: lack of benzodiazepine-like effects. Pol J Pharmacol Pharm. 1985 Sep-Oct;37(5):585-90. PubMed PMID: 2870483.

19: Beck T, Krieglstein J. The effects of tifluadom and ketazocine on behaviour, dopamine turnover in the basal ganglia and local cerebral glucose utilization of rats. Brain Res. 1986 Sep 3;381(2):327-35. PubMed PMID: 3756508.

20: Hill HF, Watanabe Y, Shibuya T. Differential, postnatal ontogeny of opiate and benzodiazepine receptor subtypes in rat cerebral cortex: binding characteristics of tifluadom and brotizolam. Jpn J Pharmacol. 1984 Sep;36(1):15-21. PubMed PMID: 6094900.